Myeloma; living better and living longer - a look at the advances

References

• Wisløff F, Eika S, Hippe E, et al. Measurement of health-related quality of life in multiple myeloma. Nordic Myeloma Study Group. Br J Haematol. 1996;92(3):604–613.
   Google Scholar
• Stead ML, Brown JM, Velikova G, et al. Development of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma. European Organization for Research and Treatment of Cancer Study Group on Quality of Life. Br J Haematol. 1999;104(3):605–611.
   Google Scholar
• Gulbrandsen N, Hjermstad MJ, Wisløff F, et al. Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences. Eur J Haematol. 2004;72(3):172–180.
   Google Scholar
• National Cancer Institute. 2016. Surveillance epidemiology and end results program. SEER stat fact sheets on multiple myeloma [Internet]. Bethesda (MD): National Cancer Institute. [cited 2013 Apr 24]. Available from: https://seer.cancer.gov/statfacts/html/mulmy.html
   Google Scholar
• Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial ofautologous bone marrow transplantationand chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996;335(2):91–97.
   Google Scholar
• Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348(19):1875–1883.
   Google Scholar
• Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516–2520.
   Google Scholar
• Anderson KC. The 39th David A. Karnofsky lecture: bench-to-bedside translation of targeted therapies in multiple myeloma. J Clin Oncol. 2012;30(4):445–452.
   Google Scholar
• National Cancer Comprehensive Network [Internet]. Fort Washington (PA). NCCN clinical practice guidelines in oncology: multiplemyeloma. [ cited 2011 Mar 10]. Available from: http://wwwnccnorg/professionals/physician_gls/PDF/myelomapdf
   Google Scholar
• Fouquet G, Bories C, Guidez S, et al. Pomalidomide for multiple myeloma. Expert Rev Hematol. 2014;7(6):719–731.
   Google Scholar
• Kim Y, Schmidt-Wolf IG. Lenalidomide in multiple myeloma. Expert Rev Anticancer Ther. 2015;15(5):491–497.
   Google Scholar
• Merin NM, Kelly KR. Clinical use of proteasome inhibitors in the treatment of multiple myeloma. Pharmaceuticals (Basel). 2014;8(1):1–20.
   Google Scholar
• Muchtar E, Gertz MA, Magen H. A practical review on carfilzomib in multiple myeloma. Eur J Haematol. 2016;96(6):564–577.
   Google Scholar
• Shirley M. Ixazomib: first global approval. Drugs. 2016;76(3):405–411.
   Google Scholar
• Atanackovic D, Steinbach M, Radhakrishnan SV, et al. Immunotherapies targeting CD38 in multiple myeloma. Oncoimmunology. 2016;5(11):e1217374.
   Google Scholar
• Hofmeister CC, Lonial S. How to integrate Elotuzumab and Daratumumab into therapy for multiple myeloma. J Clin Oncol. 2016;34(36):4421–4430.
   Google Scholar
• Laubach JP, Paba Prada CE, Richardson PG, et al. Daratumumab, Elotuzumab, and the development of therapeutic monoclonal antibodies in multiple myeloma. Clin Pharmacol Ther. 2017;101(1):81–88.
   Google Scholar
• Verelst SGR, Blommestein HM, Karim-Kos HE, et al. Trends in incidence and survival of multiple myeloma in the Netherlands in the last two decades. Results from a national population based study [abstract]. Proceedings of the 53rd annual meeting of the American Society of Hematology (ASH), 2011 Dec 10–13, San Diego, CA, USA. Blood. 2011;118(21):Abstract 5071.
   Google Scholar
• Verelst S, Karim-Kos H, Blommestein H, et al. Are we making progress? Survival in plasma cell malignancies in the era of novel treatments a population based study of 17.790 patients in The Netherlands [abstract]. Proceedings of the 17th congress of the European Hematology Association (EHA), 2012 Jun 14–17, Amsterdam, NL. Haematologica. 2012;97(s1):Abstract242.
   Google Scholar
• Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib, thalidomide and dexamethasone compared with thalidomide and dexamethasone as induction before and consolidation therapy after double autologous stem cell transplantation in newly diagnosed multiple myeloma: results from a randomized phase III study. Lancet. 2010;379(9758):2075–2085.
   Google Scholar
• Rosiñol L, Cibeira MT, Mateos MV, et al. A phase III PETHEMA/GEM study of induction therapy prior autologous stem cell transplantation in multiple myeloma: superiority of VTD (bortezomib/thalidomide/dexamethasone) over TD and VBMCP/VBAD plus bortezomib [abstract]. Proceedings of the 52rd annual meeting of the American Society of Hematology (ASH), 2010 Dec 4–7, Orlando, FL, USA. Blood. 2010;116(21):Abstract307.
   Google Scholar
• Rosiñol L, Oriol A, Teruel AI, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pre-transplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood. 2012;120(8):1589–1596.
   Google Scholar
• Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010;116(5):679–686.
   Google Scholar
• Roussel M, Lauwers-Cances V, Robillard N, et al. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome. J Clin Oncol. 2014;32(25):2712–2717.
   Google Scholar
• Cavo M, Pantani L, Pezzi A, et al. Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma. Leukemia. 2015;29(12):2429–2431.
   Google Scholar
• Moreau P, Hulin C, Macro M, et al. VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. Blood. 2016;127(21):2569–2574.
   Google Scholar
• Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol. 2012;30(24):2946–2955.
   Google Scholar
• Rajkumar VS, Jacobus S, Callander N, et al. Randomized trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed myeloma (E4A03), a trial coordinated by the Eastern Cooperative Oncology Group: analysis of response, survival, and outcome wi [abstract]. Proceedings of the 44th American society of clinical oncology (ASCO) annual meeting, 2008 May 30–Jun 3, Chicago, ILL, USA. J Clin Oncol. 2008;26(s15):Abstract8504.
   Google Scholar
• Facon T, Dimopoulos MA, Dispenzieri A, et al. Final analysis of overall survival from the first trial [abstract]. Proceedings of the 58th American Society of Hematology (ASH), 2016 Dec 3–6, San Diego, CA, USA. Blood. 2016;128(22):Abstract653.
   Google Scholar
• Fayers PM, Palumbo A, Hulin C, et al. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood. 2011;118(5):1239–1247.
   Google Scholar
• San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906–917.
   Google Scholar
• Pönisch W, Mitrou PS, Merkle K, et al. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone—a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol. 2006;132(4):205–212.
   Google Scholar
• Björkstrand B, Iacobelli S, Hegenbart U, et al. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. J Clin Oncol. 2011;29(22):3016–3022. Erratum in: J Clin Oncol. 2011;29:3721.
   Google Scholar
• Stewart KA, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142–152.
   Google Scholar
• Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374(17):1621–1634.
   Google Scholar
• Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621–631.
   Google Scholar
• Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387(10027):1551–1560.
   Google Scholar
• Molassiotis A, Wilson B, Blair S, et al. Unmet supportive care needs, psychological well-being and quality of life in patients living with multiple myeloma and their partners. Psychooncology. 2011;20(1):88–97.
   Google Scholar
• Kuyken W, Orley J, Hudelson P, et al. Quality of life assessment across cultures. Int J Mental Health. 1994;23:5–28.
   Google Scholar
• The World Health Organization Quality of Life assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med. 1995;41(10):1403–1409.
   Google Scholar
• European Medicines Agency [Internet]. London (UK). Committee for Medicinal Products for Human use (CHMP): reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products. [ cited 2005 Jul 27]. Available from: http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003637.pdf
   Google Scholar
• Food and Drug Administration. Washington (DC). U.S Department of Health and Human Services Food and Drug Administration Guidance for Industry: patient-reported outcome measures. Use in medical product development to support labeling claims. [ cited 2009 Dec]. Available from: http://www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf
   Google Scholar
• Society for Quality of Life Research. Milwaukee (WI). [cited Sep 2012]. Available from: https://link.springer.com/article/10.1007%2Fs11136-012-0252-1
   Google Scholar
• Petrucci MT, Kyriakou C, Leleu X, et al. Levels of discordance between patients? And physicians? Perception of patients? Health-related quality of life in relapse/refractory multiple myeloma? A cross-cultural perspective [oral presentation]. Proceedings of the 20th congress of the European Hematology Association (EHA); Haematologica 2015 Jun 11–14; Vienna, A. p. Abstract:S146.
   Google Scholar
• Land KC, Michalos AC, Sirgy J. Handbook of social indicators and quality of life research. New York (NY): Springer Science & Business Media; 2011.
   Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
   Google Scholar
• Cocks K, Cohen D, Wisløff F, et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer. 2007;43(11):1670–1678.
   Google Scholar
• Kvam AK, Fayers PM, Wisloff F. Responsiveness and minimal important score differences in quality-of-life questionnaires: a comparison of the EORTC QLQ-C30 cancer-specific questionnaire to the generic utility questionnaires EQ-5D and 15D in patients with multiple myeloma. Eur J Haematol. 2011;87(4):330–337.
   Google Scholar
• Proskorovsky I, Lewis P, Williams CD, et al. Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma. Health Qual Life Outcomes. 2014 Mar 11;12:35. DOI:10.1186/1477-7525-12-35
   Google Scholar
• Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: properties, application, and interpretation. Health Qual Life Outcomes. 2003;1(79):1–7.
   Google Scholar
• Weis J, Tomaszewski KA, Hammerlid E, et al. International psychometric validation of an EORTC quality of life module measuring cancer related fatigue (EORTC QLQ-FA12). J Natl Cancer Inst. 2017 May 1;109(5). DOI:10.1093/jnci/djw273
   Google Scholar
• Postma TJ, Aaronson NK, Heimans JJ, et al.; EORTC Quality of Life Group. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer. 2005;41(8):1135–1139.
   Google Scholar
• Osborne TR, Ramsenthaler C, de Wolf-Linder S, et al. Understanding what matters most to people with multiple myeloma: a qualitative study of views on quality of life. BMC Cancer. 2014;14:496. DOI:10.1186/1471-2407-14-496
   Google Scholar
• Osborne TR, Ramsenthaler C, Schey SA, et al. Improving the assessment of quality of life in the clinical care of myeloma patients: the development and validation of the Myeloma Patient Outcome Scale (MyPOS). BMC Cancer. 2015;15:280. DOI:10.1186/s12885-015-1261-6
   Google Scholar
• Ramsenthaler C, Osborne TR, Gao W, et al. The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study. BMC Cancer. 2016;16:427. DOI:10.1186/s12885-016-2410-2
   Google Scholar
• Mokkink LB, Terwee CB, Patrick DL, et al. The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes. J Clin Epidemiol. 2010 Jul;63(7):737–745.
   Google Scholar
• Kvam AK, Fayers P, Wisloff F. What changes in health-related quality of life matter to multiple myeloma patients? A prospective study. Eur J Haematol. 2010;84(4):345–353.
   Google Scholar
• Cocks K, King MT, Velikova G, et al. Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. Eur J Cancer. 2012;48(11):1713–1721.
   Google Scholar
• Gulbrandsen N, Wisløff F, Brinch L, et al. Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support. Med Oncol. 2001;18(1):65–77.
   Google Scholar
• Khalafallah A, McDonnell K, Dawar HU, et al. Quality of life assessment in multiple myeloma patients undergoing dose-reduced tandem autologous stem cell transplantation. Mediterr J Hematol Infect Dis. 2011;3(1):e2011057.
   Google Scholar
• Sherman AC, Simonton S, Latif U, et al. Changes in quality-of-life and psychosocial adjustment among multiple myeloma patients treated with high-dose melphalan and autologous stem cell transplantation. Biol Blood Marrow Transplant. 2009;15(1):12–20.
   Google Scholar
• Frödin U, Börjeson S, Lyth J, et al. A prospective evaluation of patients’ health-related quality of life during auto-SCT: a 3-year follow-up. Bone Marrow Transplant. 2011;46(10):1345–1352.
   Google Scholar
• Uyl-de Groot CA, Buijt I, Gloudemans IJ, et al. Health related quality of life in patients with multiple myeloma undergoing a double transplantation. Eur J Haematol. 2005;74(2):136–143.
   Google Scholar
• Wijermans P, Schaafsma M, Termorshuizen F, et al. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 study. J Clin Oncol. 2010;28(19):3160–3166.
   Google Scholar
• Verelst SG, Termorshuizen F, Uyl-de Groot CA, et al. Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial. Ann Hematol. 2011;90(12):1427–1439.
   Google Scholar
• Waage A, Gimsing P, Fayers P, et al. Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood. 2010;116(9):1405–1412.
   Google Scholar
• Gulbrandsen N, Waage A, Gimsing P, et al. A randomised placebo controlled study with melphalan/prednisone vsmelphalan/prednisone/thalidomide: quality of life and toxicity [abstract]. Proceedings of the 13th congress of the European Hematology Association (EHA), 2008 Jun 12–15, Copenhagen, DK. Haematologica. 2008;93(s1):Abstract0209.
   Google Scholar
• Stewart AK, Trudel S, Bahlis NJ, et al. A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial. Blood. 2013;121(9):1517–1523.
   Google Scholar
• Dhawan R, Meunier J, Regnault A, et al. Impact of complete response on health-related quality of life in newly diagnosed multiple myeloma patients: results from the VISTA trial. Proceedings of the 12th International Myeloma Workshop (IMW), Washington, DC, USA, 2009. Clin Lymphoma Myeloma. 2009;9:Abstract 352.
   Google Scholar
• Dhawan R, Robinson D, Meunier J, et al. Sustained health-related quality of life (HRQoL) improvement in newly diagnosed multiple myeloma patients treated with bortezomib/melphalan/prednisone versus melphalan/prednisone: results from the VISTA trial. Proceedings of the 51st annual meeting of the American Society of Hematology (ASH), 2009 Dec 5–8, New Orleans, LA, USA. Blood. 2009;114(22):Abstract1881.
   Google Scholar
• Delforge M, Dhawan R, Robinson D Jr, et al. Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial. Eur J Haematol. 2012;89(1):16–27.
   Google Scholar
• Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348(26):2609–2617.
   Google Scholar
• Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352(24):2487–2498.
   Google Scholar
• Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007;110(19):3557–3560.
   Google Scholar
• Lee SJ, Richardson PG, Sonneveld P, et al. Healthrelated quality of life (HRQL) associated with bortezomib compared with high-dose dexamethasone in relapsed multiple myeloma (MM): results from APEX study. Proceedings of the 41th American Society of Clinical Oncology (ASCO) annual meeting, 2005 May 12–17, Chicago, ILL, USA. J Clin Oncol. 2005;23:Abstract 6535.
   Google Scholar
• Niesvizky R, Flinn IW, Rifkin RM, et al. Phase 3b UPFRONT study: safety and efficacy of weekly bortezomib maintenance therapy after bortezomib-based induction regimens in elderly, newly diagnosed multiple myeloma patients. Proceedings of the 52nd annual meeting of the American Society of Hematology (ASH), 2010 Dec 4–7, Orlando, FL, USA. Blood. 2010;116(21):Abstract619.
   Google Scholar
• Niesvizky R, Reeves J, Flinn I, et al. Phase 3b UPFRONT study: interim results from a community-based prospective randomized trial evaluating three bortezomib-based regimens in elderly, newly diagnosed multiple myeloma patients. Proceedings of the 15th congress of the European Hematology Association (EHA), 2010 Jun 10–13, Barcelona, E. Haematologica. 2010;95(s2):144:Abstract0358.
   Google Scholar
• Niesvizky R, Flinn IW, Rifkin R, et al. Patient-reported quality of life (QoL) in elderly, newly diagnosed multiple myeloma (MM) patients receiving bortezomib-based combinations: results from all randomized patients in the community-based, phase 3b UPFRONT study. Proceedings of the 53rd annual meeting of the American Society of Hematology (ASH), 2011 Dec 10–13, San Diego, CA, USA. Blood. 2011;118(21):Abstract1864.
   Google Scholar
• Niesvizky R, Flinn I, Rifkin R, et al. Patient-reported quality of life (QOL) in previously untreated, elderly multiple myeloma (MM) patients treated with bortezomib-based regimens: results from the phase 3b UPFRONT study. Proceedings of the 16th congress of the European Hematology Association (EHA), 2011 Jun 9–12, London, UK. Haematologica. 2011;96(s1):Abstract0298.
   Google Scholar
• Niesvizky R, Flinn IW, Rifkin R, et al. Community-based phase IIIB trial of three UPFRONT bortezomib-based myeloma regimens. J Clin Oncol. 2015;33(33):3921–3929.
   Google Scholar
• Richardson PG, Barlogie B, Berenson J, et al. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial. Cancer. 2006;106(6):1316–1319.
   Google Scholar
• Viala M, Bhakar AL, de la Loge C, et al. Patient-reported outcomes helped predict survival in multiple myeloma using partial least squares analysis. J Clin Epidemiol. 2007;60(7):670–679.
   Google Scholar
• Dimopoulos M, Delforge M, Hajek R, et al. Melphalan, prednisone and lenalidomide followed by lenalidomide maintenance improves health-related quality of life (HRQoL), with newly diagnosed multiple myeloma (NDMM) patients ≥65 years benefiting from delays in disease progression. Proceedings of the 53rd annual meeting of the American Society of Hematology (ASH), 2011 Dec 10–13, San Diego, CA, USA. Blood. 2011;118(21):Abstract3157.
   Google Scholar
• Dimopoulos M, Palumbo A, Hajek R, et al. Melphalan, prednisone and lenalidomide followed by lenalidomide maintenance displays treatment characteristics favourable to global quality of life in newly diagnosed multiple myeloma (NDMM) patients ≥65 years. Proceedings of the 53rd annual meeting of the American Society of Hematology (ASH), 2011 Dec 10–13, San Diego, CA, USA. Blood. 2011;118(21):Abstract3988.
   Google Scholar
• Dimopoulos MA, Delforge M, Hájek R, et al. Lenalidomide plus melphalan and prednisone followed by lenalidomide maintenance provides favourable efficacy and health-related quality-of-life in newly diagnosed multiple myeloma patients ≥65 years. Proceedings of the 16th congress of the European Hematology Association (EHA), 2011 Jun 9–12, London, UK. Haematologica. 2011;96(s1):Abstract0880.
   Google Scholar
• Dimopoulos MA, Delforge M, Hajek R, et al. Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial. Haematologica. 2013;98(5):784–788.
   Google Scholar
• Alegre A, Oriol-Rocafiguera A, Garcia-Larana J, et al. Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience. Leuk Lymphoma. 2012;53(9):1714–1721.
   Google Scholar
• Delforge M, Minuk L, Eisenmann JC, et al. Health-related quality of life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide. Haematologica. 2015;100(6):826–833.
   Google Scholar
• Abonour R, Durie BGM, Jagannath S, et al. Health-related quality of life of patients with newly diagnosed multiple myeloma receiving any or lenalidomide maintenance after autologous stem cell transplant in the Connect® MM disease registry. Proceedings of the 58th annual meeting of the American Society of Hematology (ASH), 2016 Dec 3–6, San Diego, CA, USA. Blood. 2016;128(22):Abstract537.
   Google Scholar
• Kyriakou C, Murphy P, Petrucci MT, et al. Health-related quality of life in lenalidomide and bortezomib treated patients with relapsed/refractory multiple myeloma. Proceedings of the 57th annual meeting of the American Society of Hematology (ASH), 2015 Dec 5–8, Orlando, CA, USA. Blood. 2015;126(23):Abstract2085.
   Google Scholar
• Stewart AK, Dimopoulos MA, ‘asMasszi T, et al. Health-related quality-of-life results from the open-label, randomized, phase III ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma. J Clin Oncol. 2016;34(32):3921–3930.
   Google Scholar
• Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17:27−38.
   Google Scholar
• Ludwig H, Moreau P, Dimopoulos MA, et al. Health related quality of life results from the open-label, randomized, phase III Endeavor trial evaluating carfilzomib and dexamethasone versus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Proceedings of the 58th annual meeting of the American Society of Hematology (ASH), 2016 Dec 3–6, San Diego, CA, USA. Blood. 2016;128(22):Abstract3309.
   Google Scholar
• Leleu X, Masszi T, Bahlis NJ, et al. Patient-reported quality of life with ixazomib-lenalidomide-dexamethasone (IRD) vs placebo-Rd in relapse/refractory multiple myeloma patients in the global, placebo-controlled Tourmaline-MM1 study. Proceedings of the 21st congress of the European Hematology Association (EHA), 2016 Jun 9–12, Copenaghen, DK. Haematologica. 2016;101(s1):Abstract660.
   Google Scholar
• Paul S, Kochuparambil ST, Thompson CA, et al. Quality of life and outcomes in multiple myeloma patients. Proceedings of the 56th annual meeting of the American Society of Hematology (ASH), 2014, Dec 6–9, San Francisco, CA, USA. Blood. 2014;124(21):Abstract2605.
   Google Scholar
• Nielsen LK, Jarden M, Andersen CL, et al. Health-related quality of life (HRQoL) measurements in multiple myeloma patients obtained by EORTC QLQ-C30; a critical review of interpreting HRQoL data in longitudinal studies. Proceedings of the 58th annual meeting of the American Society of Hematology (ASH), 2016 Dec 3–6, San Diego, CA, USA. Blood. 2016;128(22):Abstract540.
   Google Scholar
• Sonneveld P, Verelst SG, Lewis P, et al. Review of health-related quality of life data in multiple myeloma patients treated with novel agents. Leukemia. 2013;27(10):1959–1969.
   Google Scholar